Science Advances

Supplementary Materials

This PDF file includes:

  • Fig. S1. No increase in mature AMs following the subcutaneous administration of rGM-CSF (20 ng) to LPL−/− neonatal pups on DOB, PND1, and PND2.
  • Fig. S2. No disruption of alveolarization observed after intranasal neonatal rGM-CSF therapy.
  • Fig. S3. Increased SP-D in LPL−/− PND3 neonatal pups.

Download PDF

Files in this Data Supplement: